Bacil Pharma Ltd. reported unaudited standalone earnings results for the third quarter and nine months ended December 31, 2016. For the quarter, the company has posted loss from operations before other income, interest and exceptional items was INR 0.280 million against INR 0.316 million a year ago. Loss from ordinary activities before tax and net loss was INR 0.055 million against INR 0.271 million a year ago. Basic and diluted loss per share was INR 0.01 against INR 0.05 a year ago. For the nine months, the company has posted loss from operations before other income, interest and exceptional items was INR 1.038 million against INR 1.003 million a year ago. Loss from ordinary activities before tax and net loss for the period was INR 0.428 million against INR 0.713 million a year ago. Basic and diluted loss per share was INR 0.07 against INR 0.12 a year ago.